NovMetaPharma Co., Ltd.

As of June 30, 2020, NovMetaPharma Co., Ltd. carries a market capitalization of 343.27B, placing it among publicly traded companies globally. Its enterprise value stands at 342.72B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2020, NovMetaPharma Co., Ltd. has 8.96M shares outstanding.

These figures are as of June 30, 2020.

As of June 30, 2020, NovMetaPharma Co., Ltd. maintains a current ratio of 3.64, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2020.

As of the close on October 23, 2026, NovMetaPharma Co., Ltd.'s stock has declined approximately 71.34% over the past 52 weeks. The 50-day moving average sits at 4,695.90, while the 200-day moving average is 8,211.23.

These figures cover the twelve months ended June 30, 2020. EBITDA reached -11.08B, while operating income came in at -11.33B.

These figures are as of June 30, 2020. Total book value stands at 1.60B, with working capital of 1.28B providing operational flexibility.

These figures cover the twelve months ended June 30, 2020.

NovMetaPharma Co., Ltd.'s most recent stock split took place on November 21, 2016 with a 20:27 split ratio.